Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1)

被引：54

作者：

Bellini, Angela ^{[1
,2
,3
]}

Poetschger, Ulrike ^{[4
,5
]}

Bernard, Virginie ^{[6
]}

Lapouble, Eve ^{[7
]}

Baulande, Sylvain ^{[6
]}

Ambros, Peter F. ^{[5
]}

Auger, Nathalie ^{[8
,9
]}

Beiske, Klaus ^{[10
,11
]}

Bernkopf, Marie ^{[5
]}

Betts, David R. ^{[12
]}

Bhalshankar, Jaydutt ^{[1
,2
,3
]}

Bown, Nick ^{[13
]}

de Preter, Katleen ^{[14
]}

Clement, Nathalie ^{[1
,2
,3
]}

Combaret, Valerie ^{[15
]}

de Mora, Jaime Font ^{[16
]}

George, Sally L. ^{[17
]}

Jimenez, Irene ^{[1
,2
,3
]}

Jeison, Marta ^{[18
]}

Marques, Barbara ^{[19
]}

Martinsson, Tommy ^{[20
]}

Mazzocco, Katia ^{[21
]}

Morini, Martina ^{[22
]}

Muehlethaler-Mottet, Annick ^{[23
,24
]}

Noguera, Rosa ^{[25
]}

Pierron, Gaelle ^{[7
]}

Rossing, Maria ^{[26
]}

Taschner-Mandl, Sabine ^{[5
]}

Van Roy, Nadine ^{[14
]}

Vicha, Ales ^{[27
,28
]}

Chesler, Louis ^{[29
]}

Balwierz, Walentyna ^{[30
]}

Castel, Victoria ^{[31
]}

Elliott, Martin ^{[32
]}

Kogner, Per ^{[33
]}

Laureys, Genevieve ^{[34
]}

Luksch, Roberto ^{[35
]}

Malis, Josef ^{[27
,28
]}

Popovic-Beck, Maja ^{[24
,36
]}

Ash, Shifra ^{[37
]}

Delattre, Olivier ^{[2
,3
,6
]}

Valteau-Couanet, Dominique ^{[38
]}

Tweddle, Deborah A. ^{[39
]}

Ladenstein, Ruth ^{[40
,41
]}

Schleiermacher, Gudrun ^{[1
,2
,3
]}

机构：

[1] Inst Curie, Equipe SiR RTOP Rech Translat Oncol Pediat, Paris, France

[2] Inst Curie, Lab Genet & Biol Canc, INSERM U830, Paris, France

[3] Inst Curie, SIREDO Care Innovat & Res Children Adolescents &, Paris, France

[4] Dept Studies & Stat & Integrated Res, Vienna, Austria

[5] St Anna Childrens Canc Res Inst, Vienna, Austria

[6] Inst Curie, Inst Curie Genom Excellence ICGex Platform, Res Ctr, Paris, France

[7] Inst Curie, Hosp Grp, Serv Genet, Unite Genet Somat, Paris, France

[8] Serv Genet Tumeurs, Villejuif, France

[9] Inst Gustave Roussy, Villejuif, France

[10] Univ Oslo, Oslo Univ Hosp, Dept Pathol, Oslo, Norway

[11] Univ Oslo, Med Fac, Oslo, Norway

[12] Childrens Hlth Ireland Crumlin, Dept Clin Genet, Dublin, Ireland

[13] Newcastle upon Tyne Hosp NHS Fdn Trust, Northern Genet Serv, Newcastle Upon Tyne, Tyne & Wear, England

[14] Univ Ghent, Ghent, Belgium

[15] Ctr Leon Berard, Translat Res Lab, Lyon, France

[16] Inst Invest Sanitaria La Fe, Valencia, Spain

[17] Inst Canc Res, Div Clin Studies, London, England

[18] Tel Aviv Univ, Schneider Childrens Med Ctr Israel, Tel Aviv, Israel

[19] Inst Nacl Saude Doutor Ricardo Jorge, Dept Genet Humana, Lisbon, Portugal

[20] Sahlgrens Univ Hosp, Gothenburg, Sweden

[21] IRCCS Ist Giannina Gaslini, Dept Pathol, Genoa, Italy

[22] IRCCS Ist Giannina Gaslini, Lab Mol Biol, Genoa, Italy

[23] Lausanne Univ Hosp, Pediat Hematol Oncol Res Lab, Lausanne, Switzerland

[24] Univ Lausanne, Lausanne, Switzerland

[25] Univ Valencia, Med Sch, Dept Pathol, Incl Hlth Res Inst CIBERONC, Madrid, Spain

[26] Copenhagen Univ Hosp, Rigshosp, Ctr Genom Med, Copenhagen, Denmark

[27] Charles Univ Prague, Fac Med 2, Dept Paediat Haematol & Oncol, Prague, Czech Republic

[28] Univ Hosp Motol, Prague, Czech Republic

[29] Inst Canc Res, Div Clin Studies, Paediat Tumour Biol, Sutton, Surrey, England

[30] Jagiellonian Univ Med Coll, Inst Pediat, Dept Pediat Oncol & Hematol, Krakow, Poland

[31] Hlth Res Inst La Fe, Clin & Translat Oncol Res Grp, Valencia, Spain

[32] Leeds Childrens Hosp, Leeds Gen Infirm, Leeds, W Yorkshire, England

[33] Karolinska Univ Hosp, Stockholm, Sweden

[34] Ghent Univ Hosp, Princess Elisabeth Childrens Hosp, Dept Paediat Haematol & Oncol, Ghent, Belgium

[35] Ist Nazl Tumori, Fdn IRCCS, Paediat Oncol, Milan, Italy

[36] Lausanne Univ Hosp, Pediat Hematol Oncol Unit, Lausanne, Switzerland

[37] Ruth Rappaport Childrens Hosp, Rambam Hlth Care Campus, Haifa, Israel

[38] Gustave Roussy, Dept Oncol Pediat, Villejuif, France

[39] Newcastle Univ, Wolfson Childhood Canc Res Ctr, Newcastle Ctr Canc, Translat & Clin Res Inst, Newcastle Upon Tyne, Tyne & Wear, England

[40] St Anna Childrens Hosp, St Anna Childrens Canc Res Inst, Dept Studies & Stat & Integrated Res, Vienna, Austria

[41] Med Univ Vienna, Dept Paediat, Vienna, Austria

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 30期

关键词：

SEGMENTAL CHROMOSOMAL ALTERATIONS; ACTIVATING MUTATIONS; PEDIATRIC-PATIENTS; CRIZOTINIB; REVEALS; RELAPSE; KINASE; REARRANGEMENTS; HETEROGENEITY; CHEMOTHERAPY;

D O I：

10.1200/JCO.21.00086

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PURPOSE In neuroblastoma (NB), the ALK receptor tyrosine kinase can be constitutively activated through activating point mutations or genomic amplification. We studied ALK genetic alterations in high-risk (HR) patients on the HR-NBL1/SIOPEN trial to determine their frequency, correlation with clinical parameters, and prognostic impact. MATERIALS AND METHODS Diagnostic tumor samples were available from 1,092 HR-NBL1/SIOPEN patients to determine ALK amplification status (n = 330), ALK mutational profile (n = 191), or both (n = 571). RESULTS Genomic ALK amplification (ALKa) was detected in 4.5% of cases (41 out of 901), all except one with MYCN amplification (MNA). ALKa was associated with a significantly poorer overall survival (OS) (5-year OS: ALKa [n = 41] 28% [95% CI, 15 to 421; no-ALKa [n = 860] 51% [95% CI, 47 to 54], [P < .001]), particularly in cases with metastatic disease. ALK mutations (ALKm) were detected at a clonal level (> 20% mutated allele fraction) in 10% of cases (76 out of 762) and at a subclonal level (mutated allele fraction 0.1%-20%) in 3.9% of patients (30 out of 762), with a strong correlation between the presence of ALKm and MNA (P< .001). Among 571 cases with known ALKa and ALKm status, a statistically significant difference in OS was observed between cases with ALKa or clonal ALKm versus subclonal ALKm or no ALK alterations (5-year OS: ALKa En = 19], 26% [95% CI, 10 to 47], clonal ALKm En = 65] 33% [95% CI, 21 to 44], subclonal ALKm (n = 22) 48% [95% CI, 26 to 67], and no alteration En = 465], 51% [95% CI, 46 to 55], respectively; P = .001). Importantly, in a multivariate model, involvement of more than one metastatic compartment (hazard ratio [HR], 2.87; P < .001), ALKa (HR, 2.38; P = .004), and clonal ALKm (HR, 1.77; P = .001) were independent predictors of poor outcome. CONCLUSION Genetic alterations of ALK (clonal mutations and amplifications) in HR-NB are independent predictors of poorer survival. These data provide a rationale for integration of ALK inhibitors in upfront treatment of HR-NB with ALK alterations. (C) 2021 by American Society of Clinical Oncology

引用

页码：3377 / +

页数：28

共 55 条

[1] A mechanistic classification of clinical phenotypes in neuroblastoma [J].

Ackermann, Sandra ;

Cartolano, Maria ;

Hero, Barbara ;

Welte, Anne ;

Kahlert, Yvonne ;

Roderwieser, Andrea ;

Bartenhagen, Christoph ;

Walter, Esther ;

Gecht, Judith ;

Kerschke, Laura ;

Volland, Ruth ;

Menon, Roopika ;

Heuckmann, Johannes M. ;

Gartlgruber, Moritz ;

Hartlieb, Sabine ;

Henrich, Kai-Oliver ;

Okonechnikov, Konstantin ;

Altmueller, Janine ;

Nuernberg, Peter ;

Lefever, Steve ;

de Wilde, Bram ;

Sand, Frederik ;

Ikram, Fakhera ;

Rosswog, Carolina ;

Fischer, Janina ;

Theissen, Jessica ;

Hertwig, Falk ;

Singhi, Aatur D. ;

Simon, Thorsten ;

Vogel, Wenzel ;

Perner, Sven ;

Krug, Barbara ;

Schmidt, Matthias ;

Rahmann, Sven ;

Achter, Viktor ;

Lang, Ulrich ;

Vokuhl, Christian ;

Ortmann, Monika ;

Buettner, Reinhard ;

Eggert, Angelika ;

Speleman, Frank ;

O'Sullivan, Roderick J. ;

Thomas, Roman K. ;

Berthold, Frank ;

Vandesompele, Jo ;

Schramm, Alexander ;

Westermann, Frank ;

Schulte, Johannes H. ;

Peifer, Martin ;

Fischer, Matthias .

SCIENCE, 2018, 362 (6419) :1165-+

[2] Ultra-high density SNParray in neuroblastoma molecular diagnostics [J].

Ambros, Inge M. ;

Brunner, Clemens ;

Abbasi, Reza ;

Frechl, Christian ;

Ambros, Peter F. .

FRONTIERS IN ONCOLOGY, 2014, 4 :1-41

[3] A Multilocus Technique for Risk Evaluation of Patients with Neuroblastoma [J].

Ambros, Inge M. ;

Brunner, Bettina ;

Aigner, Gerhard ;

Bedwell, Clare ;

Beiske, Klaus ;

Benard, Jean ;

Bown, Nick ;

Combaret, Valerie ;

Couturier, Jerome ;

Defferrari, Raffaella ;

Gross, Nicole ;

Jeison, Marta ;

Lunec, John ;

Marques, Barbara ;

Martinsson, Tommy ;

Mazzocco, Katia ;

Noguera, Rosa ;

Schleiermacher, Gudrun ;

Speleman, Frank ;

Stallings, Ray ;

Tonini, Gian Paolo ;

Tweddle, Deborah A. ;

Valent, Alexander ;

Vicha, Ales ;

Van Roy, Nadine ;

Villamon, Eva ;

Ziegler, Andrea ;

Preuner, Sandra ;

Drobics, Mario ;

Ladenstein, Ruth ;

Amann, Gabriele ;

Schuit, Robert J. L. ;

Poetschger, Ulrike ;

Ambros, Peter F. .

CLINICAL CANCER RESEARCH, 2011, 17 (04) :792-804

[4] International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee [J].

Ambros, P. F. ;

Ambros, I. M. ;

Brodeur, G. M. ;

Haber, M. ;

Khan, J. ;

Nakagawara, A. ;

Schleiermacher, G. ;

Speleman, F. ;

Spitz, R. ;

London, W. B. ;

Cohn, S. L. ;

Pearson, A. D. J. ;

Maris, J. M. .

BRITISH JOURNAL OF CANCER, 2009, 100 (09) :1471-1482

[5] Pseudo-observations in survival analysis [J].

Andersen, Per Kragh ;

Perme, Maja Pohar .

STATISTICAL METHODS IN MEDICAL RESEARCH, 2010, 19 (01) :71-99

[6] Study of chromatin remodeling genes implicates SMARCA4 as a putative player in oncogenesis in neuroblastoma [J].

Bellini, Angela ;

Bessoltane-Bentahar, Nadia ;

Bhalshankar, Jaydutt ;

Clement, Nathalie ;

Raynal, Virginie ;

Baulande, Sylvain ;

Bernard, Virginie ;

Danzon, Adrien ;

Chicard, Mathieu ;

Colmet-Daage, Leo ;

Pierron, Gaelle ;

Le Roux, Laura ;

Planchon, Julien M. ;

Combaret, Valerie ;

Lapouble, Eve ;

Corradini, Nadege ;

Thebaud, Estelle ;

Gambart, Marion ;

Valteau-Couanet, Dominique ;

Michon, Jean ;

Louis-Brennetot, Caroline ;

Janoueix-Lerosey, Isabelle ;

Defachelles, Anne-Sophie ;

Bourdeaut, Franck ;

Delattre, Olivier ;

Schleiermacher, Gudrun .

INTERNATIONAL JOURNAL OF CANCER, 2019, 145 (10) :2781-2791

[7] Deep Sequencing Reveals Occurrence of Subclonal ALK Mutations in Neuroblastoma at Diagnosis [J].

Bellini, Angela ;

Bernard, Virginie ;

Leroy, Quentin ;

Frio, Thomas Rio ;

Pierron, Gaelle ;

Combaret, Valerie ;

Lapouble, Eve ;

Clement, Nathalie ;

Rubie, Herve ;

Thebaud, Estelle ;

Chastagner, Pascal ;

Defachelles, Anne Sophie ;

Bergeron, Christophe ;

Buchbinder, Nimrod ;

Taque, Sophie ;

Auvrignon, Anne ;

Valteau-Couanet, Dominique ;

Michon, Jean ;

Janoueix-Lerosey, Isabelle ;

Delattre, Olivier ;

Schleiermacher, Gudrun .

CLINICAL CANCER RESEARCH, 2015, 21 (21) :4913-4921

[8] Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study [J].

Berbegall, Ana P. ;

Bogen, Dominik ;

Poetschger, Ulrike ;

Beiske, Klaus ;

Bown, Nick ;

Combaret, Valerie ;

Defferrari, Raffaella ;

Jeison, Marta ;

Mazzocco, Katia ;

Varesio, Luigi ;

Vicha, Ales ;

Ash, Shifra ;

Castel, Victoria ;

Coze, Carole ;

Ladenstein, Ruth ;

Owens, Cormac ;

Papadakis, Vassilios ;

Ruud, Ellen ;

Amann, Gabriele ;

Sementa, Angela R. ;

Navarro, Samuel ;

Ambros, Peter F. ;

Noguera, Rosa ;

Ambros, Inge M. .

BRITISH JOURNAL OF CANCER, 2018, 118 (11) :1502-1512

[9] The genetic tumor background is an important determinant for heterogeneous MYCN-amplified neuroblastoma [J].

Bogen, Dominik ;

Brunner, Clemens ;

Walder, Diana ;

Ziegler, Andrea ;

Abbasi, Reza ;

Ladenstein, Ruth L. ;

Noguera, Rosa ;

Martinsson, Tommy ;

Amann, Gabriele ;

Schilling, Freimut H. ;

Ussowicz, Marek ;

Benesch, Martin ;

Ambros, Peter F. ;

Ambros, Inge M. .

INTERNATIONAL JOURNAL OF CANCER, 2016, 139 (01) :153-163

[10] ALK Mutations Confer Differential Oncogenic Activation and Sensitivity to ALK Inhibition Therapy in Neuroblastoma [J].

Bresler, Scott C. ;

Weiser, Daniel A. ;

Huwe, Peter J. ;

Park, Jin H. ;

Krytska, Kateryna ;

Ryles, Hannah ;

Laudenslager, Marci ;

Rappaport, Eric F. ;

Wood, Andrew C. ;

McGrady, Patrick W. ;

Hogarty, Michael D. ;

London, Wendy B. ;

Radhakrishnan, Ravi ;

Lemmon, Mark A. ;

Mosse, Yael P. .

CANCER CELL, 2014, 26 (05) :682-694

← 1 2 3 4 5 6 →